Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-09-01
1997-10-07
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31475
Patent
active
056748744
ABSTRACT:
7-ethyl-10-hydroxy camptothecin (HECPT), an active metabolite of the camptothecin analog CPT-11 which is used as an anticancer drug, is poorly soluble in water. Because of its poor water solubility, HECPT has not been directly administered by parenteral or oral routes in human patients for the purpose of inhibiting the growth of cancer cells. There is also unpredictable interpatient variability in the metabolic production of HECPT from CPT-11 which limits the utility of CPT-11. This invention overcomes these limitations by teaching novel pharmaceutically acceptable lactone stable HECPT formulations for the direct administration of lactone stable HECPT formulations orally or parenterally to patients with various forms of cancer.
REFERENCES:
patent: 3219529 (1965-11-01), Nash
patent: 3699230 (1972-10-01), Beauchamp et al.
patent: 4082881 (1978-04-01), Chen et al.
patent: 4228162 (1980-10-01), Luzzi et al.
patent: 4339276 (1982-07-01), Miyasaka et al.
patent: 4399282 (1983-08-01), Miyasaka et al.
patent: 4473692 (1984-09-01), Miyasaka et al.
patent: 4545880 (1985-10-01), Miyasaka et al.
patent: 4604463 (1986-08-01), Miyasaka et al.
patent: 4713246 (1987-12-01), Begum et al.
patent: 4734284 (1988-03-01), Terada et al.
patent: 4778891 (1988-10-01), Tagawa et al.
patent: 5004758 (1991-04-01), Boehm et al.
patent: 5061800 (1991-10-01), Wall et al.
patent: 5180722 (1993-01-01), Kalsha
patent: 5225404 (1993-07-01), Giovannella et al.
patent: 5227380 (1993-07-01), Wall et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5468754 (1995-11-01), Hausheer et al.
patent: 5496830 (1996-03-01), Shapiro
patent: 5597829 (1997-01-01), Hausheer
patent: 5604233 (1997-02-01), Hausheer
patent: 5633260 (1997-05-01), Hausheer
Emerson, David L., et al; In Vivo Antitumor Activity of Two New Seven-Substituted Water Soluble Camptothecin Analogues; Cancer Research 55:603-609; Feb. 1995.
Gupta, Elora, et al; Metabolic Fate of Irinotecan In Humans: Correlation Of Glucuronidation With Diarrhea; Cancer Research 54:3723-3725, Jul. 1994.
Haas, Naomi B., et al.; Phase I/Pharmacokinetic Study of Topotecan by 24-Hour Continuous Infusion Weekly; Cancer Research 54:1220-1226, Mar. 1994.
Hinz, Hellmuth R., et al.; Pharmacokinetic of the In Vivo and In Vitro Conversion of 9-Nitro-20(s)-Camptothecin in Humans, Dogs, and Mice; Cancer Research 54:3096-3100, Jun. 1994.
Houghton, Peter J., et al; Therapeutic Efficacy of the Topoisomerase I -1-piperidino)-carbonyloxy-camptothecin against Human Tumor Xenografts: Lack of Cross-Resistance In Vivo in Tumors With Acquired Resistance To The Topoisomerase I Inhibotor 9-Dimethylaminomethyl-10-hydroxycampothecin; Cancer Research 53:2823-2829, Jun. 1993.
Luzzio, Michael J., et al; Synthesis And Antitumor Activity of Novel Water Soluble Derivatives Of Camptothecin As Specific Inhibitors of Topoisomerase I; Journal Of Medicinal Chemistry, 38:3,395-401.
Moertel, Charles G., et al; Phase II Study of Camptothecin (NSC-100880) in the Treatment Of Advances Gastrointestinal Cancer; Cancer Chemotherapy Reports Part 1 vol. 56, No. 1, Feb. 1972.
Rivory, Laurent P., et al; Kinetics of the In Vivo Interconversion of the Carboxylate and Lactone Forms of Irinotecan (CPT-11) and of Its Metabolite SN-38 in Patients; Cancer Research 54:6330-6333, Dec. 1994.
Supko, Jeffrey G., et al; Pharmacokinetics of the 9-Amino and 10, 1-Methylenedioxy Derivatives of Camptothecin in Mice; Cancer Research 53:3062-3069, Jul. 1993.
Wall, Monroe E., et al; Camptothecin And Taxol: Discovery To Clinic-Thirteenth Bruce F. Cain Memorial Award Lecture; Cancer Research 55:753-760, Feb. 1995.
Wall, Monroe E., et al; Camptothecin; AntiCancer Agents Based on Natura Product Models, Chapter 12, pp. 417-436, 1980.
Wall, Monroe E., et al; Plant Antitumor Agents. 30.sup.1a,b Synthesis And Structure Activity Of Novel Campthothecin Analogs; J. Med. Chem., 36:2689-2700, 1993.
Haridas Kochat
Hausheer Frederick H.
BioNumerik Pharmaceuticals, Inc.
Daus Donald G.
Dodd Thomas J.
LandOfFree
Lactone stable formulation of 7-ethyl 10-hydroxy camptothecin an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactone stable formulation of 7-ethyl 10-hydroxy camptothecin an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactone stable formulation of 7-ethyl 10-hydroxy camptothecin an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2357585